Business Wire

FISHAWACK

1.8.2019 15:02:09 CEST | Business Wire | Press release

Share
2e Creative Joins Global Healthcare Communications Group Fishawack

2e Creative , an internationally recognised healthcare marketing strategy firm focused on launching pharmaceutical and medical device products, has joined the Fishawack Group , after receiving investment from the global healthcare communications group. The 2e deal strengthens Fishawack as one of the largest independent healthcare communications organisations worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190801005540/en/

“2e has been on an exhilarating growth trajectory for the past several years,” 2e CEO Ross Toohey said. “We chose Fishawack over a host of other potential investors because their global footprint, expansive capabilities, and entrepreneurial culture represented the greatest advantage for our employees and clients. This is truly the next evolutionary leap for 2e and the brands we serve.”

Fishawack is a global healthcare communications group with offices in London, Oxford, Brighton and Manchester, UK, as well as Philadelphia, New York, and San Diego, USA; 2e adds to the group’s US footprint. The firm’s core strengths in medical communications, strategic consulting, and creative, fits nicely with 2e’s expertise in strategy, creative, digital marketing, sales training, and internal communications. With this breadth of capabilities, Fishawack and 2e can now support clients throughout the entire product development, launch, and growth lifecycle. With the 2e partnership, the Fishawack Group now boasts over 750 employees worldwide, making it among the largest independent healthcare agencies globally.

“Fishawack is one of the new generation of leaders in healthcare communications. We’re challenging the major agency networks by fostering a uniquely collaborative culture across our agency collective,” Fishawack CEO Oliver Dennis said. “We offer the capabilities, scale, and geographical coverage to offer healthcare brands a fresh, new type of partnership value. We’re excited about 2e’s portfolio, capabilities, and brilliant people. Ross has built a great entrepreneurial culture, and we can’t wait to work with the 2e team.”

This partnership is particularly notable for 2e because it comes on the heels of the agency’s appointment to the MM&M Top 100 Healthcare Agencies worldwide, as well as 2e’s three consecutive victories (2015, 2016, 2017) as MM&M “Healthcare Agency of the Year.” Between 2e and sister agencies Dudnyk , Carling Communications , Blue Latitude Health , and Healthcircle , the Fishawack Group is among the most award winning in the field of healthcare marketing.

“We’re very deliberate about the agencies we invest in,” Fishawack Group President Gail Flockhart said. “Clients demand seamlessly blended capabilities, so it’s important that we build collaborative allegiances across the Fishawack Group. It’s best for our clients and our people. 2e brings executive training and organisational optimisation capabilities to the group.”

Advisors to Fishawack included KPMG, Addleshaw Goddard LLP, and financial backers LDC and LGT Capital Partners. 2e’s advisors included Results International, Stoll Keenon Ogden PLLC, and Clifton Larson Allen.

About 2e Creative

Founded in 1999, 2e Creative is a launch and growth agency featuring Fortune 50 clients across pharma, medical device, and research biotech. The agency’s core competencies include branding, marketing strategy, digital marketing, sales training, and meeting/event production. 2e has over 150 employees and operations in Missouri, Indiana, Texas, and California.

About the Fishawack Group

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Manchester, Oxford, London, and Brighton), the USA (Philadelphia, PA, New York, NY, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).

Fishawack comprises two international divisions, Fishawack Medical Communications , developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative , offering strategic planning, creative development, advertising and promotion, and tactical execution.

We have built our reputation on excellence, creativity, and transparency.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye